Our Pricing

What Side Effects Can Occur When Mounjaro Is Prescribed?

Published on: June 03, 2026

Understanding mounjaro side effects UK prescribed patients may experience is essential before starting tirzepatide treatment. At Cured Pharmacy, our UK-registered clinical team provides transparent information about what to expect, helping you make informed decisions about your weight management journey with proper medical support throughout.

Common Gastrointestinal Side Effects of Mounjaro

The most frequently reported mounjaro side effects UK prescribed patients experience are gastrointestinal in nature. In the SURMOUNT-1 trial, nausea occurred in 29% of participants on the 10mg dose and 33% on the 15mg dose, compared to 8% receiving placebo [1]. These symptoms typically emerge during dose escalation and diminish over subsequent weeks as the body adapts to tirzepatide.

Diarrhoea affected approximately 23% of trial participants, whilst vomiting occurred in 11-13% depending on the dose [1]. Constipation, though less discussed, was reported by 13-16% of patients. These gastrointestinal effects reflect tirzepatide's mechanism of action — slowing gastric emptying and modulating gut hormones to reduce appetite and improve glycaemic control.

Most gastrointestinal side effects are mild to moderate in severity and resolve within 4-8 weeks of maintaining a stable dose. Our superintendent pharmacist Tarun Kumar advises patients to eat smaller, more frequent meals and avoid high-fat foods during the initial treatment phase to minimise discomfort whilst the body adjusts.

Managing Nausea and Digestive Symptoms

Practical management strategies can significantly reduce the impact of gastrointestinal side effects. Stay well-hydrated throughout the day, particularly if experiencing vomiting or diarrhoea. Ginger tea, small protein-rich snacks, and avoiding lying down immediately after eating can help manage nausea without additional medication.

If symptoms persist beyond the first month or become severe enough to interfere with daily activities, contact your prescriber. They may recommend temporarily maintaining your current dose rather than escalating, or in rare cases, reducing the dose until tolerance improves. Never adjust your Mounjaro dose without clinical guidance from your UK prescriber.

Injection Site Reactions and Administration Effects

Injection site reactions occurred in approximately 3-5% of patients across the SURMOUNT trials [1]. These typically present as mild redness, itching, or slight swelling at the injection location and usually resolve within 24-48 hours without intervention. Rotating injection sites between the abdomen, thigh, and upper arm reduces the likelihood of persistent localised reactions.

Some patients report temporary fatigue or mild headaches, particularly during the first few weeks of treatment. In clinical trials, fatigue was reported by 7% of participants on tirzepatide compared to 4% on placebo [2]. These symptoms generally diminish as the body adapts to the medication's metabolic effects.

Proper injection technique significantly influences tolerability. Allow the Mounjaro KwikPen to reach room temperature before injecting, cleanse the skin thoroughly with an alcohol wipe, and inject slowly over 5-10 seconds. Our clinical team provides detailed administration guidance during your consultation to optimise comfort and effectiveness.

Metabolic and Systemic Side Effects

Hypoglycaemia (low blood sugar) is uncommon with Mounjaro monotherapy, occurring in less than 2% of patients without diabetes in clinical trials [1]. However, risk increases when tirzepatide is combined with insulin or sulphonylureas. Symptoms include shakiness, sweating, confusion, and rapid heartbeat — if you experience these, consume 15-20g of fast-acting carbohydrate and contact your prescriber.

Changes in heart rate have been observed in some patients, with a mean increase of 2-4 beats per minute noted across tirzepatide studies [2]. Whilst generally not clinically significant, patients with pre-existing cardiovascular conditions require closer monitoring. Your UK prescriber will assess your cardiovascular history during the initial consultation to determine suitability.

Gallbladder-related events, including cholelithiasis (gallstones) and cholecystitis (gallbladder inflammation), occurred in approximately 1.5% of patients during extended tirzepatide treatment [3]. Rapid weight loss itself increases gallstone risk regardless of medication. Seek immediate medical attention if you experience severe upper abdominal pain, particularly if accompanied by fever or yellowing of the skin.

Monitoring and Clinical Oversight

Regular monitoring ensures side effects are identified and managed promptly. Your prescriber may recommend periodic blood tests to assess kidney function, liver enzymes, and lipid profiles, particularly during the first six months of treatment. These assessments help differentiate medication effects from underlying health changes.

At Cured Pharmacy, our UK-registered clinical team remains available throughout your treatment journey. If you experience unexpected symptoms or have concerns about side effects, contact us on (+44) 116 4646009 for guidance from our pharmacists who specialise in weight management therapies.

Rare but Serious Mounjaro Side Effects UK Patients Should Recognise

Pancreatitis, whilst rare (occurring in less than 0.2% of clinical trial participants), represents a serious potential side effect requiring immediate medical attention [3]. Symptoms include severe persistent abdominal pain radiating to the back, often accompanied by nausea and vomiting. If you experience these symptoms, stop taking Mounjaro and seek emergency medical care immediately.

Acute kidney injury has been reported in patients experiencing severe gastrointestinal side effects leading to dehydration. Maintaining adequate hydration is particularly important during episodes of vomiting or diarrhoea. Signs of dehydration include dark urine, dizziness upon standing, and decreased urination frequency — contact your prescriber if these develop.

Thyroid C-cell tumours occurred in animal studies at doses substantially higher than human therapeutic levels [4]. Whilst no causal relationship has been established in humans, Mounjaro is contraindicated in patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Your prescriber will screen for these conditions during your consultation.

How Mounjaro Side Effects Compare to Alternative Weight Loss Treatments

When comparing mounjaro side effects UK prescribed patients experience versus other GLP-1 receptor agonists, the profile is broadly similar but with some notable differences. Semaglutide (Wegovy) shows comparable gastrointestinal side effect rates, with nausea occurring in 44% of participants in the STEP-1 trial versus 33% with tirzepatide's highest dose [5]. However, tirzepatide's dual GIP/GLP-1 mechanism may offer improved tolerability for some patients.

Liraglutide (Saxenda), requiring daily injections, shows similar gastrointestinal effects but with potentially higher discontinuation rates due to injection frequency and tolerability concerns. In the SCALE trial, 9.9% of participants discontinued liraglutide due to adverse events compared to 6.2% discontinuing tirzepatide in SURMOUNT-1 [1][6].

Orlistat-based treatments like Xenical produce distinctly different side effects, primarily gastrointestinal effects related to fat malabsorption rather than appetite regulation. These include oily stools, faecal urgency, and flatulence with discharge — effects that occur with dietary fat intake rather than as systemic medication effects. Your UK prescriber will discuss which side effect profile aligns better with your lifestyle and medical history.

Choosing Based on Tolerability Profile

Individual tolerability varies significantly between patients. Some find weekly injections with transient nausea preferable to daily injections or dietary fat restrictions. Others prioritise avoiding injection-related side effects entirely. Your medical consultation at Cured Pharmacy considers your personal preferences, medical history, and lifestyle factors to recommend the most suitable treatment option.

All prescription weight loss medications available through Cured Pharmacy require clinical assessment by a UK prescriber. Our online consultation takes under 3 minutes and ensures you receive a treatment matched to your individual health profile, with ongoing support to manage any side effects that emerge during therapy.

Long-Term Safety and Side Effect Duration When Mounjaro Is Prescribed

Extended safety data from the SURMOUNT-1 trial covering 72 weeks of treatment demonstrates that most side effects diminish substantially after the dose-escalation phase [1]. Gastrointestinal symptoms peaked during weeks 8-20 when doses were being increased, then declined markedly even as patients continued on maintenance doses of 10mg or 15mg weekly.

Discontinuation rates due to adverse events remained relatively stable throughout the trial period, suggesting that patients who tolerate the initial months of treatment typically continue successfully. Only 4.3% of participants discontinued tirzepatide 10mg due to adverse events, and 7.1% discontinued the 15mg dose [1]. These rates compare favourably to other weight management interventions requiring long-term adherence.

Ongoing pharmacovigilance through the MHRA's Yellow Card scheme continues to monitor real-world safety as Mounjaro use expands across the UK. Healthcare professionals and patients are encouraged to report any suspected side effects, contributing to our evolving understanding of tirzepatide's long-term safety profile in diverse patient populations.

At Cured Pharmacy, we supply only genuine UK-licensed Mounjaro from authorised distributors, ensuring product quality and traceability. Our prices start from £124.99 for Mounjaro Weight Loss Injections, with transparent upfront pricing shown before your consultation begins. Every prescription undergoes review by our UK-registered clinical team to ensure ongoing suitability and safety.

Scientific References

1. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., ... & Bunck, M. C. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
2. Frias, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., ... & SURPASS-2 Investigators. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine, 385(6), 503–515. https://doi.org/10.1056/NEJMoa2107519 [accessed 13 August 2026]
3. Medicines and Healthcare products Regulatory Agency. (2023). Mounjaro 2.5 mg solution for injection in pre-filled pen: Summary of Product Characteristics. GOV.UK. Retrieved from https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency [accessed 13 August 2026]
4. European Medicines Agency. (2022). Assessment report: Mounjaro (tirzepatide). EMA/CHMP/765714/2022. European Medicines Agency. Retrieved from https://www.ema.europa.eu [accessed 13 August 2026]
5. Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., ... & STEP 1 Study Group. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
6. Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., ... & SCALE Obesity and Prediabetes NN8022-1839 Study Group. (2015). A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine, 373(1), 11–22. https://doi.org/10.1056/NEJMoa1411892 [accessed 13 August 2026]
7. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
8. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
9. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Side effect experiences vary between individuals, and this guide does not replace personalised medical advice from your prescriber.